{"filing":{"accession_number":"0000886163-26-000038","cik":"0000886163","ticker":"LGNYZ","company_name":"LIGAND PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"lgnd-20260605.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616326000038/lgnd-20260605.htm"},"events":[{"id":4356,"run_id":3807,"accession_number":"0000886163-26-000038","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Ligand Pharmaceuticals held its Annual Meeting of stockholders on June 5, 2026, with shareholders voting on four proposals: election of eight board directors, ratification of Ernst \u0026 Young LLP as auditor, advisory vote on named executive officer compensation, and approval of an amended 2002 Stock Incentive Plan. All proposals passed with disclosed vote tallies.","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-09","items":[{"id":5481,"accession_number":"0000886163-26-000038","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the Company's 2002 Stock Incentive Plan at the June 5, 2026 Annual Meeting. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves material modifications to an equity compensation plan that would affect director and officer compensation structures. The restated plan's approval by shareholders is a significant governance and compensation event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:04:25.662309+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5482,"accession_number":"0000886163-26-000038","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the final voting results from Ligand Pharmaceuticals' Annual Meeting of stockholders. The filing presents results for four proposals: election of eight board directors, ratification of Ernst \u0026 Young LLP as auditor, advisory vote on named executive officer compensation, and approval of an amended 2002 Stock Incentive Plan. All proposals passed with disclosed vote tallies (For, Against, Abstentions, and Broker Non-Votes where applicable).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:04:25.662309+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5481,"accession_number":"0000886163-26-000038","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the Company's 2002 Stock Incentive Plan at the June 5, 2026 Annual Meeting. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves material modifications to an equity compensation plan that would affect director and officer compensation structures. The restated plan's approval by shareholders is a significant governance and compensation event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:04:25.662309+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-09"},{"id":5482,"accession_number":"0000886163-26-000038","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the final voting results from Ligand Pharmaceuticals' Annual Meeting of stockholders. The filing presents results for four proposals: election of eight board directors, ratification of Ernst \u0026 Young LLP as auditor, advisory vote on named executive officer compensation, and approval of an amended 2002 Stock Incentive Plan. All proposals passed with disclosed vote tallies (For, Against, Abstentions, and Broker Non-Votes where applicable).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:04:25.662309+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-09"}]}